Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 19/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 16/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 14/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | HRH2 | P25021 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23914515 | 0.93 | S1PR2 (0.34) | S1PR2HRH1ADRA1AADRA1BHRH3 | |
| SCHEMBL23913182 | 0.88 | S1PR2 (0.41) | S1PR2HRH1ADRA1AADRA1BHRH3 | |
| SCHEMBL23915620 | 0.87 | S1PR2 (0.41) | S1PR2 | |
| SCHEMBL23914612 | 0.86 | HRH1 (0.36) | S1PR2HRH1ADRA1AADRA1BHRH3 | |
| SCHEMBL23909091 | 0.86 | BTK (0.34) | S1PR2 | |
| SCHEMBL23914722 | 0.84 | S1PR2 (0.36) | S1PR2HRH1ADRA1AADRA1BHRH3 | |
| SCHEMBL23909084 | 0.80 | S1PR2 (0.35) | S1PR2 | |
| SCHEMBL23915441 | 0.80 | S1PR2 (0.35) | S1PR2 | |
| SCHEMBL23915604 | 0.80 | ADRA1A (0.37) | S1PR2HRH1ADRA1AADRA1BHRH3 | |
| SCHEMBL23915621 | 0.80 | S1PR2 (0.41) | S1PR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
| CN-110869359-A | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | 加拉帕戈斯股份有限公司 | 2020-03-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | S1PR2 3/4885HRH1 385/4885ADRA1A 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.